ATP13A2 Antibody Blocking Peptide

Neurodegenerative disorders such as Parkinson and Alzheimer disease cause motor and cognitive dysfunction and belong to a heterogeneous group of common and disabling disorders. ATP13A2, otherwise known as PARK9, is a neuronal P-type ATPase gene underlying an autosomal recessive form of early-onset parkinsonism with pyramidal degeneration and dementia. ATP13A2 protein is located in the membrane of these lysosomes and is formed most strongly in the brain, especially in the substantia nigra, a brain region which is known to play a central role in Parkinson's disease.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Peptides and proteins are guaranteed for 3 months from date of receipt.

We have publications tested in 1 confirmed species: Human.

We have publications tested in 2 applications: IF/IHC, WB.

Showing Publication 1 - 1 of 1.

Publication using NB110-41486PEP	Applications	Species
Dehay B, Ramirez A, Martinez-Vicente M, Perier C, Canron MH, Doudnikoff E, Vital A, Vila M, Klein C, Bezard E. Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration. Proc Natl Acad Sci U S A. 2012-05-30 [PMID: 22647602] (IF/IHC, WB, Human)	IF/IHC, WB	Human

Array NB110-41486PEP

• ATP13A2 Antibodies
• ATP13A2 Proteins